| |
NASDAQ | Common Stock
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers.
The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.
It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors.
Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma.
The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 3, 22 | -0.66 Increased by +2.94% | -0.49 Decreased by -34.69% |
| Aug 15, 22 | -0.54 Increased by +28.00% | -0.65 Increased by +16.92% |
| May 16, 22 | -0.66 Increased by +10.81% | -0.68 Increased by +2.94% |
| Mar 28, 22 | -0.66 Increased by +9.59% | -0.61 Decreased by -8.20% |
| Nov 15, 21 | -0.68 Decreased by -15.25% | -0.80 Increased by +15.00% |
| Aug 12, 21 | -0.75 Decreased by -1.35% | -0.63 Decreased by -19.05% |
| May 14, 21 | -0.74 Increased by +43.94% | -0.71 Decreased by -4.23% |
| Mar 24, 21 | -0.73 | -0.58 Decreased by -25.86% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | 91.00 K Decreased by -85.44% | -10.19 M Decreased by -4.00% | Decreased by -11.20 K% Decreased by -614.30% |
| Jun 30, 22 | 38.00 K Decreased by -95.01% | -156.00 K Increased by +98.56% | Decreased by -410.53% Increased by +71.18% |
| Mar 31, 22 | 458.00 K Decreased by -52.98% | -10.03 M Decreased by -4.80% | Decreased by -2.19 K% Decreased by -122.87% |
| Dec 31, 21 | 1.15 M Increased by +14.14% | -10.05 M Decreased by -6.93% | Decreased by -876.88% Increased by +6.32% |
| Sep 30, 21 | 625.00 K Decreased by -5.02% | -9.80 M Decreased by -31.70% | Decreased by -1.57 K% Decreased by -38.66% |
| Jun 30, 21 | 761.00 K Decreased by -27.18% | -10.84 M Decreased by -61.52% | Decreased by -1.42 K% Decreased by -121.79% |
| Mar 31, 21 | 974.00 K Decreased by -2.70% | -9.57 M Decreased by -45.01% | Decreased by -982.34% Decreased by -49.03% |
| Dec 31, 20 | 1.00 M Increased by +169.89% | -9.40 M Decreased by -73.30% | Decreased by -936.06% Increased by +35.79% |